Pediatrics

Exposure to Maternal Diabetes Could Increase Risk of Psychiatric Disorders in Offspring

October 19, 2021

An analysis of more than 2.4 million offspring in Denmark suggests children with exposure to maternal diabetes during pregnancy were at a 15% greater risk of developing a psychiatric disorder in the first 40 years of life.

Trial Results Suggest Healthy Eating Patterns Could Reduce Cardiovascular Risk in Pediatric Patients

September 22, 2021

A Cleveland Clinic trial assessing the effects of 3 healthy eating patterns in children with overweight or obesity details the improvements in cardiovascular risk factors seen with adherence to a healthy eating pattern.

FDA Approves SKYTROFA, First Once-Weekly Treatment for Growth Hormone Deficiency in Children

August 26, 2021

With approval awarded to Ascendis Pharma on August 25, lonapegsomatropin-tcgd (SKYTROFA) becomes the first once-weekly injection approved by the FDA to deliver somatropin by sustained release over a 1-week period.

Rates of Type 1 and Type 2 Diabetes in Children Increasing Across the US

August 24, 2021

Data from the SEARCH for Diabetes in Youth Study suggests the prevalence of type 1 diabetes among youths have increased by nearly 50% from 2001-2017 and prevalence of type 2 diabetes increased by more than 95% during the same period.

Endocrine Month in Review: July 2021

July 31, 2021

July's month in review features stories related to new diabetes medications, National Kidney Foundation guidance, and FDA news. Check back in during the last weekend of each month for the next Endocrine Month in Review.

FDA Approves Semglee, Its First Interchangeable Biosimilar Insulin Product

July 29, 2021

Announced on July 28, insulin glargine-yfgn (Semglee) becomes the first interchange biosimilar insulin product to receive approval in the FDA's history and is expected to be available by the end of the year.

Exenatide Extended-Release Receives Historic FDA Approval for Use in Pediatric Type 2 Diabetes

July 23, 2021

With approval, exenatide extended-release (BYDUREON BCise) becomes the first weekly GLP-1 RA therapy to receive approval for improving glycemic control in pediatric patients aged 10-17 years with type 2 diabetes.

Prepregnancy Cardiovascular Risk Factors Play Role in Risk of Adverse Maternal, Fetal Outcomes

July 22, 2021

Analysis of more than 18 million pregnancies sheds light on the impact various prepregnancy cardiovascular risk factors, including BMI, smoking status, and diabetes, can have on risk of adverse maternal and fetal outcomes.

Endocrinology Network's Meet the Board: Elaine Apperson, MD

July 12, 2021

To allow our audience to become more acquainted with our advisory board members, Endocrinology Network will be hosting a special content series highlighting our board members, their practices, and why they were invited to help guide coverage moving forward.

Early Life BMI Plays Role in Future Diabetes and CVD Risk, Regardless of Adult BMI

June 22, 2021

Using 24 years of follow-up data from more than 12k adolescents provides insight into the impact of childhood BMI z-scores on risk of adverse health outcomes, including development of diabetes and premature myocardial infarction, in adulthood.